Abnormal Liver Test Patterns

Review total bilirubin, INR or prothrombin time, albumin, ALT, AST, and alkaline phosphatase together. ALT and AST elevations reflect hepatocellular injury; alkaline phosphatase elevation reflects cholestasis or impaired bile flow. Bilirubin may rise in either hepatocellular or cholestatic disease, while bilirubin, INR/prothrombin time, and albumin provide information about hepatic function. ScienceDirectScienceDirectEvaluation of Abnormal Liver Biochemical Test Results

Expedite evaluation when aminotransferase elevation is accompanied by elevated bilirubin and prolonged INR, because this combination signals more urgent liver disease assessment. Acute liver failure is defined clinically by acute abnormal liver blood tests in a patient without known chronic liver disease plus liver-related coagulopathy and clinically apparent hepatic encephalopathy. ScienceDirect+1ScienceDirectEvaluation of Abnormal Liver Biochemical Test ResultsScienceDirectThe clinical phenotypes of autoimmune hepatitis: A comprehensive review

Do not equate every enzyme abnormality with progressive chronic liver disease, but do not defer diagnosis when the pattern suggests a treatable cause. The decision to broaden testing should be driven by the clinical scenario, because indiscriminate testing increases false-positive results and can expose patients to unnecessary biopsy-related risk. ScienceDirectScienceDirectClinical Approach to the Patient With Abnormal Liver Test Results - ScienceDirect

Calculate R = (ALT/ULN) ÷ (alkaline phosphatase/ULN). By convention, R >5 is hepatocellular, R <2 is cholestatic, and R between 2 and 5 is mixed. Classification should use the first laboratory tests available in relation to the clinical event, particularly when DILI is considered. Wolters Kluwer+2Wolters KluwerACG Clinical Guideline: Diagnosis and Management... - Lippincotteasl eu[PDF] EASL Clinical Practice Guideline: Occupational liver diseaseseasl eu[PDF] EASL Clinical Practice Guidelines: Drug-induced liver injury

The R value directs the initial competing-etiology workup but does not establish a cause. Individual drugs can produce differing biochemical patterns among patients, and DILI remains a diagnosis of exclusion even when exposure timing is compelling. Wolters KluwerWolters KluwerACG Clinical Guideline: Diagnosis and Management... - Lippincott

For clinically significant exposure-associated liver injury, commonly used biochemical thresholds are ALT at least 5 times ULN, alkaline phosphatase at least 2 times ULN, or ALT at least 3 times ULN with total bilirubin greater than 2 times ULN. If a bone source of alkaline phosphatase is plausible, concomitant GGT elevation supports a hepatobiliary source. easl eueasl eu[PDF] EASL Clinical Practice Guideline: Occupational liver diseases

For hepatocellular or mixed DILI-pattern presentations, evaluate competing viral and autoimmune causes rather than assigning the abnormality to a medication by temporal association alone. Recommended hepatocellular-case testing includes hepatitis A and B evaluation, RNA-HCV, IgM anti-HEV, and autoimmune serology. Wolters Kluwer+1Wolters KluwerACG Clinical Guideline: Diagnosis and Management... - Lippincotteasl eu[PDF] EASL Clinical Practice Guidelines: Drug-induced liver injury

Autoimmune hepatitis should remain in the differential even when symptoms are absent. Diagnostic criteria incorporate elevated AST and ALT, total immunoglobulin levels, autoantibodies, and characteristic histologic abnormalities; asymptomatic patients can have histologic inflammation comparable to symptomatic patients. aasldaasldWhy do we treat autoimmune hepatitis with immunomodulators? | AASLD

A structured medication review is essential in every hepatocellular pattern with possible DILI. Establish chronology for prescription agents, nonprescription analgesics, herbals, dietary supplements, and recent discontinuations, then exclude competing etiologies systematically before concluding that a drug caused the injury. accessdata fda+1accessdata fda[PDF] 202293Orig1s000 - accessdata.fda.govWolters KluwerACG Clinical Guideline: Diagnosis and Management... - Lippincott

An alkaline phosphatase-predominant profile indicates cholestasis or impaired bile flow. In a cholestatic or mixed pattern with jaundice, perform ultrasound and add cholangiography to evaluate the biliary tree. ScienceDirect+1ScienceDirectEvaluation of Abnormal Liver Biochemical Test Resultseasl eu[PDF] EASL Clinical Practice Guidelines: Drug-induced liver injury

Cholestatic DILI remains an exclusion diagnosis. Drug-induced cholestasis is generally managed by withdrawal of the suspect drug; most cases improve after withdrawal, although prolonged cholestasis can occur and a minority have persistent laboratory or histologic injury. easl eueasl eu[PDF] EASL Clinical Practice Guidelines: Management of cholestatic liver ...

Do not assume a single medication has a fixed phenotype. The same drug can cause hepatocellular, cholestatic, or mixed biochemical injury in different patients; retain structural and inflammatory biliary causes in the differential even with a plausible drug exposure. Wolters KluwerWolters KluwerACG Clinical Guideline: Diagnosis and Management... - Lippincott

Obtain sequential liver tests when the initial cause is uncertain, particularly after a possible medication exposure or a transient biliary event. Serial ALT, alkaline phosphatase, bilirubin, and INR establish whether injury is resolving, evolving toward cholestasis, or developing functional impairment. accessdata fda+2accessdata fda[PDF] 202293Orig1s000 - accessdata.fda.govScienceDirectEvaluation of Abnormal Liver Biochemical Test Resultseasl eu[PDF] EASL Clinical Practice Guideline: Occupational liver diseases

Liver biopsy can support suspected DILI, define severity, and exclude competing diagnoses. It is most useful when the diagnosis remains uncertain, liver tests persist, or management depends on distinguishing autoimmune, drug-related, infiltrative, or other pathologic processes; it is not obligatory for a known hepatotoxic exposure with favorable clinical evolution. Wolters Kluwer+1Wolters KluwerACG Clinical Guideline: Diagnosis and Management... - Lippincotteasl eu[PDF] EASL Clinical Practice Guidelines: Drug-induced liver injury

For suspected steatotic liver disease in patients with metabolic risk factors, ultrasound or steatosis biomarkers plus liver enzymes can identify steatosis; serum fibrosis markers such as FIB-4, NAFLD Fibrosis Score, ELF, FibroTest, or FibroMeter separate lower-risk from medium/high-risk fibrosis groups. Medium/high-risk noninvasive results warrant specialist referral and in-depth severity assessment, including consideration of biopsy. easl eueasl eu[PDF] NAFLD-English-report.pdf - EASL